Matthew Galsky

42PUBLICATIONS
377CO-AUTHORS
Radiation therapyMedical biotechnology diagnostics (incl. biosensors)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (42)

|Jul 27, 2026
Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801).

|Jun 03, 2026
Precision Diagnostics in Prostate Cancer Treatment (PREDICT): A Phase II Multiarm Biomarker-Based Study (Alliance A032102).

|Jun 01, 2026
Additivity, Not Synergy, Underlies the Efficacy of Current Combination Regimens in Urothelial Cancer.

|May 16, 2026
TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.

|Apr 19, 2026
Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial.

|Feb 27, 2026
A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial.

Matthew D Galsky, Charlene Mantia, Michaela Bowden

Pageof 7

Frequent Collaborators

9 joint publications

Nina Bhardwaj

8 joint publications

Sacha Gnjatic

7 joint publications

Matthew Milowsky

6 joint publications

Sudeh Izadmehr